Marketplace All-in-One
Tariffs with Canada, again
· Summarized
Key takeaways
- The US and Canada are currently in a trade dispute that has resulted in significant tariffs and retaliation, affecting international trade relations.
- The US Treasury is exploring new strategies for bond buybacks, potentially utilizing its large cash reserves, but details remain unclear.
- Employer coverage for expensive drugs like GLP-1 for weight loss is declining, raising concerns about healthcare accessibility and affordability for individuals with obesity and diabetes.
- Policy decisions by employers and healthcare providers significantly influence who can access cutting-edge treatments, highlighting ongoing inequalities in healthcare.
Summary
US-Canada Trade Tensions and Tariffs
This section covers the recent escalation in the trade war between the US and Canada, where negotiations fell apart over the weekend. In response, the US imposed 50% tariffs on $20 billion worth of Canadian imports, prompting some retaliation from Canada. Julia Coronado discusses how this tit-for-tat leads to broader impacts, notably affecting US exporters and the global supply chain. The ongoing trade dispute underscores the fragile state of US-Canada trade relations and their potential economic repercussions.
US Treasury Bond Buybacks and Funding Strategies
The discussion here focuses on the US Treasury Department’s strategy to double its purchase of long-term bonds from $2 billion to at least $4 billion per issue, starting September 9th. The purpose is to reduce the supply of bonds and lower interest rates, but questions remain about how these buybacks will be financed. Reports suggest the Treasury General Account, nearly $1 trillion strong, might be used to fund this initiative. Officials have not confirmed the specifics, leaving some uncertainty about the future financial maneuvers.
Insurance Coverage for GLP-1 Drugs for Weight Loss and Diabetes
This section dives into the complexities of employer-based insurance coverage for GLP-1 drugs, which are used for diabetes and weight loss. Recent reports show a decline in coverage for weight loss treatments among large employers, with rising costs leading many to exclude these drugs. The case of Christy Turner exemplifies the challenge — her coverage was terminated, and she now buys the medication directly from manufacturers at a significantly higher cost. Experts debate whether covering these drugs long-term is financially feasible or justified due to their health benefits and potential for reducing future medical expenses, revealing disparities in healthcare access based on insurance plans.
Sponsors
- Marketplace Morning Report · Every story has an economic angle. Want some in your inbox? Subscribe to our daily or weekly newsletter.
- marketplace.org · Marketplace Morning Report is more than a radio show. Check out our original reporting and financial literacy content at marketplace.org — and consider making an investment in our future.
Show notes
Negotiations between the United States and Canada fell apart over the weekend, failing to prevent the U.S. imposing 50% tariffs on $20 billion worth of Canadian products that cover a wide array of goods. Julia Coronado, founder and president of MacroPolicy Perspectives, joins the show this morning for context on that and inflation, before we look at more long-term Treasury bonds being issued and insurance coverage problems for GLP-1 drugs.
Every story has an economic angle. Want some in your inbox? Subscribe to our daily or weekly newsletter.
Marketplace Morning Report is more than a radio show. Check out our original reporting and financial literacy content at marketplace.org — and consider making an investment in our future.
Stories featured in this episode:
Follow this show on AudioBrevity and new episodes get summarized for you. Create a free account